The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 20, 2024
Filed:
Jan. 15, 2019
Applicant:
Cls Therapeutics Limited, Saint Peter Port, GG;
Inventors:
Dmitry Dmitrievich Genkin, Saint Petersburg, RU;
Georgy Viktorovich Tets, Saint Petersburg, RU;
Viktor Veniaminovich Tets, Saint Petersburg, RU;
Assignee:
CLS THERAPEUTICS LIMITED, Saint Peter Port, GG;
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07H 21/04 (2006.01); C12N 15/63 (2006.01); C12N 15/00 (2006.01); C12N 15/86 (2006.01); C12N 9/22 (2006.01); A61K 38/46 (2006.01); A61P 35/04 (2006.01); A61P 25/28 (2006.01); A61P 1/16 (2006.01); C07K 14/005 (2006.01); G01N 33/53 (2006.01); C12Q 1/68 (2018.01); A01K 67/00 (2006.01); A61B 5/00 (2006.01); A61B 17/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); A61K 38/465 (2013.01); A61K 48/005 (2013.01); A61K 48/0058 (2013.01); A61P 1/16 (2018.01); A61P 25/28 (2018.01); A61P 35/04 (2018.01); C07K 14/005 (2013.01); C12N 9/22 (2013.01); C12Q 1/68 (2013.01); G01N 33/5308 (2013.01); A01K 2207/12 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); A61B 5/4848 (2013.01); A61B 2017/00893 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14145 (2013.01); C12N 2830/008 (2013.01); G01N 2333/435 (2013.01); G01N 2800/7028 (2013.01);
Abstract
The invention relates to the liver-specific delivery and/or expression of an enzyme which has a deoxyribonuclease (DNase) activity for enhanced clearance of cell free DNA (cfDNA) accumulated in hepatic porto-sinusoidal circulation and the use of such liver-specific delivery and/or expression for treatment of various diseases and conditions, including cancer and neurodegeneration.